2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
Montreh Tavakkoli, Stefan K. Barta
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical outcomes. Our understanding of its molecular makeup continues to improve risk stratification, and artificial-intelligence and ctDNA-based analyses have the potential to enhance risk assessment and disease monitoring. R-CHOP and Pola-R-CHP are used in the frontline setting; chimeric antigen receptor therapy (CART) is now the new standard-of-care for most with primary refractory disease; both CART and autologous stem cell transplantation are utilized in the relapsed and refractory setting. In this review, we summarize the classification and management of DLBCL with an emphasis on recent advances in the field.
Topics & Concepts
Risk stratificationLymphomaMedicineCartDiffuse large B-cell lymphomaChimeric antigen receptorDiseaseOncologyTransplantationRituximabCHOPIntensive care medicineInternal medicineImmunotherapyCancerMechanical engineeringEngineeringLymphoma Diagnosis and TreatmentCAR-T cell therapy researchCNS Lymphoma Diagnosis and Treatment